Corcept Therapeutics Incorporated (CORT) Q3 2026 earnings results
Corcept Therapeutics Incorporated (CORT) reported Q3 2026 results on Nov 3, 2026, 4:09:08 PM ET: GAAP EPS $1.01 vs. $0.84 expected (beat by 20.2%); revenue $340.47M vs. $336.37M expected (beat by 1.2%). Outlook: Reiterated 2026 revenue guidance of $1.1 – $1.2 billion.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | $1.01 | $0.84 | Beat by 20.2% |
| Revenue | $340.47M | $336.37M | Beat by 1.2% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 3, 2026, 4:09:08 PM ET. Nexqual published them 39 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 64.0% from $207.64M; GAAP diluted EPS was $1.01 vs. $0.16 (+531.3%).
Stock reaction
The results came out after the market closed. CORT closed at $79.22 on November 4, 2026, down 3.3% from its $81.93 close on November 3, 2026 before the results. Latest: $72.07 as of 11:53 AM ET, −12.0% since the pre-release close.
Questions and answers
Did Corcept Therapeutics Incorporated beat earnings expectations?
Yes. Corcept Therapeutics Incorporated reported GAAP EPS of $1.01 against an average analyst estimate of $0.84 (beat by 20.2%), and revenue of $340.47M against $336.37M expected (beat by 1.2%).
What were Corcept Therapeutics Incorporated's Q3 2026 earnings and revenue?
GAAP diluted EPS of $1.01 and revenue of $340.47M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 64.0% from $207.64M; GAAP diluted EPS was $1.01 vs. $0.16 (+531.3%).
When did Corcept Therapeutics Incorporated report Q3 2026 earnings?
Nov 3, 2026, 4:09:08 PM ET, in an SEC 8-K filing (Item 2.02).
How did CORT stock react to the earnings?
The results came out after the market closed. CORT closed at $79.22 on November 4, 2026, down 3.3% from its $81.93 close on November 3, 2026 before the results. Latest: $72.07 as of 11:53 AM ET, −12.0% since the pre-release close.
What did Corcept Therapeutics Incorporated say about its outlook?
Reiterated 2026 revenue guidance of $1.1 – $1.2 billion.
More on CORT
CORT stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 3, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 10, 2026 at 16:53 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:53 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt